Original Article

Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Hope Northrup MD a,*, Darcy A. Krueger MD PhD b, on behalf of the International Tuberous Sclerosis Complex Consensus Group

a Division of Medical Genetics, Department of Pediatrics, University of Texas Medical School at Houston, Houston, Texas
b Division of Neurology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

ABSTRACT

BACKGROUND: Tuberous sclerosis complex is highly variable in clinical presentation and findings. Disease manifestations continue to develop over the lifetime of an affected individual. Accurate diagnosis is fundamental to implementation of appropriate medical surveillance and treatment. Although significant advances have been made in the past 15 years in the understanding and treatment of tuberous sclerosis complex, current clinical diagnostic criteria have not been critically evaluated or updated since the last clinical consensus conference in 1998. METHODS: The 2012 International Tuberous Sclerosis Complex Consensus Group, comprising 79 specialists from 14 countries, was organized into 12 subcommittees, each led by a clinician with advanced expertise in tuberous sclerosis complex and the relevant medical subspecialty. Each subcommittee focused on a specific disease area with important diagnostic implications and was charged with reviewing prevalence and specificity of disease-associated clinical findings and their impact on suspecting and confirming the diagnosis of tuberous sclerosis complex. RESULTS: Clinical features of tuberous sclerosis complex continue to be a principal means of diagnosis. Key changes compared with 1998 criteria are the new inclusion of genetic testing results and reducing diagnostic classes from three (possible, probable, and definite) to two (possible, definite). Additional minor changes to specific criterion were made for additional clarification and simplification. CONCLUSIONS: The 2012 International Tuberous Sclerosis Complex Diagnostic Criteria provide current, updated means using best available evidence to establish diagnosis of tuberous sclerosis complex in affected individuals.

Keywords: diagnostic criteria, clinical features, tuberous sclerosis

See related articles on pages 223 and 255.

Introduction

Tuberous sclerosis complex (TSC) was initially described approximately 150 years ago by von Recklinghausen in 1862.1 TSC is an extremely variable disease that can affect virtually any organ in the body. The most common findings are benign tumors in the skin, brain, kidneys, lung, and heart that lead to organ dysfunction as the normal parenchyma is replaced by a variety of cell types.2 Disease manifestations in different organ systems can vary widely between even closely related individuals and the protean nature of the condition can make clinical diagnosis challenging. TSC was underdiagnosed until the 1980s when individuals with less severe manifestations of the disease began to be recognized. Before the 1980s, incidence rates for TSC were quoted at between 1/100,000 and 1/200,000.3,4 Recent studies estimate a frequency of 1/6000 to 1/10,000 live births and a population prevalence of around 1 in 20,000.5,6 Although TSC was recognized to be a genetic disease more than 100 years ago,7 the underlying molecular etiology was not unraveled until the discovery of the two causative genes, TSC1 and TSC2.8,9

The second International Tuberous Sclerosis Complex Consensus Conference was held June 13-14, 2012, in Washington, DC. Seventy-nine experts (Appendix) from 14...
The identification of either a TSC1 or TSC2 pathogenic mutation in DNA from normal tissue is sufficient to make a definite diagnosis of tuberous sclerosis complex (TSC). A pathogenic mutation is defined as a mutation that clearly inactivates the function of the TSC1 or TSC2 proteins (e.g., out-of-frame indel or nonsense mutation), prevents protein synthesis (e.g., large genomic deletion), or is a missense mutation whose effect on protein function has been established by functional assessment (www.lovd.nl/TSC1, www.lovd/TSC2, and Hoogeveen-Westerveld et al., 2012 and 2013). Other TSC1 or TSC2 variants whose effect on function is less certain do not meet these criteria, and are not sufficient to make a definitive diagnosis of TSC. Note that 10% to 25% of TSC patients have no mutation identified by conventional genetic testing, and a normal result does not exclude TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC.

A. Genetic diagnostic criteria

The identiﬁcations of either a TSC1 or TSC2 pathogenic mutation in DNA from normal tissue is sufﬁcient to make a deﬁnite diagnosis of tuberous sclerosis complex (TSC). A pathogenic mutation is deﬁned as a mutation that clearly inactivates the function of the TSC1 or TSC2 proteins (e.g., out-of-frame indel or nonsense mutation), prevents protein synthesis (e.g., large genomic deletion), or is a missense mutation whose effect on protein function has been established by functional assessment (www.lovd.nl/TSC1, www.lovd/TSC2, and Hoogeveen-Westerveld et al., 2012 and 2013). Other TSC1 or TSC2 variants whose effect on function is less certain do not meet these criteria, and are not sufﬁcient to make a deﬁnite diagnosis of TSC. Note that 10% to 25% of TSC patients have no mutation identiﬁed by conventional genetic testing, and a normal result does not exclude TSC, or have any effect on the use of clinical diagnostic criteria to diagnose TSC.

B. Clinical diagnostic criteria

Major features
1. Hypomelanotic macules (≥3, at least 5-mm diameter)
2. Angioﬁbromas (≥3) or ﬁbrous cephalic plaque
3. Ungual ﬁbromas (≥2)
4. Shagreen patch
5. Multiple retinal hamartomas
6. Cortical dysplasias
7. Subependymal nodules
8. Subependymal giant cell astrocytoma
9. Cardiac rhabdomyoma
10. Lymphangioleiomyomatosis (LAM)
11. Angiomyolipomas (≥2)

Minor features
1. “Confetti” skin lesions
2. Dental enamel pits (≥3)
3. Intraoral ﬁbromas (≥2)
4. Retinal achromatic patch
5. Multiple renal cysts
6. Nonrenal hamartomas

Definite diagnosis: Two major features or one major feature with ≥2 minor features
Possible diagnosis: Either one major feature or ≥2 minor features

© 2013 Elsevier Inc. All rights reserved. Printed in the United States of America. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not changed in any way.

Genetic diagnostic criteria

Comprehensive and reliable screens for TSC1 and TSC2 mutations are well-established, and many pathogenic mutations have been identiﬁed (www.lovd.nl/TSC1, www.lovd/TSC2). The recommendation of the Genetics Panel was to make identiﬁcation of a pathogenic mutation in TSC1 or TSC2 an independent diagnostic criterion, sufﬁcient for the diagnosis or prediction of TSC regardless of the clinical ﬁndings (Table part A). This will facilitate the diagnosis of TSC in some, particularly young individuals, allowing earlier implementation of surveillance and treatment with potential for better clinical outcomes. A “pathogenic” mutation was deﬁned as a mutation that clearly prevents protein synthesis and/or inactivates the function of the TSC1 or TSC2 proteins (e.g., nonsense mutation or frameshift mutations, large genomic deletions) or is a missense mutation whose effect on protein function has been established by functional assessment. TSC1 and TSC2 genetic variants whose functional effect is less certain are not deﬁnitely pathogenic and would not be considered a major diagnostic criterion. A signiﬁcant fraction (10-25%) of TSC patients have no mutation identiﬁed by conventional genetic testing. Therefore, a normal result does not exclude TSC. Nonetheless, if the mutation in an affected relative is known, testing for that mutation has very high predictive value for family members. Assembled experts at the Consensus Conference agreed with the recommendation that identiﬁcation of a pathogenic mutation in TSC1 or TSC2 is an independent diagnostic criterion.

Clinical diagnostic criteria

In addition to diagnosis by genetic analysis, the clinical diagnostic criteria used to establish the diagnosis of TSC were also reviewed at the conference. Special attention was
given to evaluate the sensitivity and specificity of clinical findings with respect to TSC diagnosis. Panels were assigned to the following focus areas for this process, and specific attempts were made to refine and simplify the clinical diagnostic criteria that included 11 major features and nine minor features according to the 1998 Conference. The individual panels were organized as follows: (1) dermatology and dentistry; (2) ophthalmology; (3) brain structure, tumors, and epilepsy; (4) epilepsy; (5) TSC-associated neuro-psychiatric disorders; (6) cardiology; (7) pulmonology; (8) nephrology; (9) endocrinology; (10) gastroenterology; and (11) care integration. The recommendations of each panel were presented to the entire congress for discussion, modification if necessary, and final approval. The new, updated diagnostic clinical criteria now include 11 major features and six minor features (Table part B).

Dermatologic and dental features

The dermatology and dental panel recommended retaining the existing mucocutaneous criteria and suggested minor changes regarding their number, size, or nomenclature. The major features (with changes italicized) include: (1) hypomelanotic macules (≥3, at least 5-mm diameter), (2) angiofibromas (≥3) or fibrous cephalic plaque, (3) ungual fibromas (≥2), and (4) shagreen patch. The revised minor features include: (1) “confetti” skin lesions, (2) dental enamel pits (≥3), and (3) intraoral fibromas (≥2).

Nearly 100% of individuals affected with TSC have skin or dental findings of the disease that are easily detectable on physical examination. It is therefore important that these features be highlighted to aid in bringing TSC patients to medical attention.

Hypomelanotic macules

Hypomelanotic macules are a significant feature because they are observed in about 90% of individuals with TSC, they typically appear at birth or infancy, and they may be a presenting sign of TSC (Fig 1).15–21 At the 1998 Consensus, it was stipulated that an individual must have three or more hypopigmented macules, because one or two lesions are relatively common in the general population.22,23 In the updated criteria, it was recommended that hypomelanotic macules meet a size requirement of at least 5-mm diameter to distinguish hypomelanotic macules from smaller and more numerous “confetti” lesions. In addition, it was suggested that poliosis, circumscribed areas of hypomelanosis of hair, be included in the count of hypomelanotic macules.

Angiofibromas or fibrous cephalic plaque

Facial angiofibromas occur in about 75% of TSC patients (Fig 2).15,16,18,21 With onset typically between ages 2 and 5 years.24 Although most TSC patients have several facial angiofibromas, milder cases of TSC with limited facial angiofibromas have been described. However, because one or two isolated sporadic lesions may be observed in the general population,25 the presence of at least three facial angiofibroma lesions is now recommended to meet this major criteria for TSC. Multiple facial angiofibromas have also been observed in Birt-Hogg-Dubé (BHD) syndrome, and multiple endocrine neoplasia type 1 (MEN1).26,27 In these conditions, the age of onset of angiofibromas is later than in TSC. Therefore, multiple facial angiofibromas remains a major feature for diagnosis when their onset occurs in childhood. In the unusual circumstance when angiofibromas have their onset in adulthood, they should be considered as a minor feature and the differential diagnosis expanded to include BHD and MEN1. When angiofibromas are few or later in onset, a skin biopsy may be required to confirm the clinical diagnosis.

The forehead plaque is observed in about 25% of TSC patients and this feature was paired with angiofibromas for the diagnostic criteria in 1998 (Fig 3A). The panel recommended changing the terminology from forehead plaque to fibrous cephalic plaque. This term was created to increase awareness that these fibrous plaques, although often located unilaterally on the forehead, may occur on other parts of the face or scalp (Fig 3B). Fibrous cephalic plaques, which are histologically similar to angiofibromas, may be the most specific skin finding for TSC.

Ungual fibromas

Ungual fibromas were retained as a major feature (Fig 4). The previous designation as “nontraumatic” was eliminated because recall of trauma may be unreliable and trauma may play a role in the formation of TSC ungual fibromas.28 This designation was replaced with the requirement that they be
multiple (≥2) because ungual fibromas that occur in the general population in response to trauma are usually solitary.29 The redundant phrase “ungual and periungual fibromas” was replaced with “ungual fibromas” used to encompass both periungual and subungual fibromas. Ungual fibromas are less common than some of the other TSC skin findings, with a frequency of about 20% overall but as high as 80% in older adults.15,16,28 The greater frequency in adults is due to later onset, typically in the second decade or later.18,21 Therefore, their utility in diagnosis is usually limited to adolescents and adults.24

Shagreen patch

The presence of a shagreen patch was retained as a major feature, but the criterion was updated by deletion of “connective tissue nevus” because this term encompasses a variety of skin lesions with excessive dermal connective tissue that are not necessarily associated with TSC. Shagreen patches commonly take the form of large plaques on the lower back that have a bumpy or orange-peel surface, and this clinical appearance is nearly always specific for TSC (Fig 5). Smaller collagenomas on the trunk exhibit the same histologic changes as shagreen patches but are less specific for TSC because they may also occur as an isolated finding or in other genetic syndromes including MEN1,26 BHD,30 and Cowden syndrome.31 Shagreen patches are observed in about 50% of individuals with TSC and typically have their onset in the first decade of life.15,16,18,21

“Confetti” skin lesions

Confetti skin lesions are numerous 1- to 3-mm hypopigmented macules scattered over regions of the body such as the arms and legs.31 Their frequency varies widely in different studies, from 3% in children to about 58% overall.15,24 Despite their relatively low frequency, confetti lesions may still be useful for diagnosis and they were retained as a minor feature. Their utility in adults is limited by the fact that many adults in the general population develop similar-appearing lesions as a consequence of chronic sun exposure. In such cases, the diagnosis of confetti lesions may be supported by a history of onset in
the first decade of life or by asymmetric involvement of one body region over another.

Dental enamel pits

Dental enamel pits, previously included as a minor feature listed as “multiple, randomly distributed pits in dental enamel” were again included as a minor feature (Fig 6). The designation was simplified to dental enamel pits for the entire dentition. Dental pits are much more common in TSC patients than the general population, with Mlynarczyk reporting 100% of adult TSC patients (n = 50) as having pitting compared with 7% of 250 adult control subjects. Because they are relatively common in the population, they are listed as a minor feature.

Intraoral fibromas

Gingival fibromas have long been associated with TSC and were listed as a minor feature in the 1998 consensus document (Fig 7). They occur in about 20-50% of individuals with TSC, with greater frequency in adults than children.

Bone cysts

Bone cysts were included in the 1998 criteria as a minor feature of TSC. Because of the lack of specificity for TSC and because the feature is rarely identified in the absence of additional TSC clinical features, a decision was made to delete “bone cysts” from the clinical diagnostic criteria.

Ophthalmologic features

Multiple retinal hamartomas

The finding of more than one retinal hamartoma was determined to be significant and specific enough to retain as a major feature (Fig 8). These lesions have similar histologic features to the tubers located in the brains of TSC patients. They are observed in 30-50% of TSC patients and it is not unusual to have multiple lesions in the same patient. The prevalence of retinal hamartomas in non-TSC populations is not known, but rare case reports have been made and a recent series of 3573 healthy term newborns identified only two cases of astrocytic hamartomas in that population. Fortunately, these lesions in TSC usually do not cause problems with vision and are a good marker for the disease, particularly in young children who might not yet have many other features.

Retinal achromatic patch

The presence of a retinal achromatic patch was determined at the 1998 conference to constitute a minor feature (Fig 9). The assembled experts at the 2012 conference concurred with the previous recommendation. Retinal achromatic patches are basically areas of hypopigmentation on the retina. These patches have been noted to occur in 39% of TSC
Incidence in the general population is estimated at 1 in 20,000.41

Central nervous system features

Because medical problems relating to the brain result in the greatest morbidity and mortality in TSC, three panels at the 2012 Consensus Conference devoted their efforts to central nervous system–related findings of TSC. The panels were: (3) brain structure, tubers, and tumors; (4) epilepsy; and (5) TSC-associated neuropsychiatric disorders. The three panels were in agreement that there should be three neurological findings categorized as major features and that the minor feature of cerebral white matter radial migration lines should be subsumed into one of the major features as reviewed in the following sections. Thus, findings relating to the central nervous were streamlined.

Cortical dysplasias

Cortical dysplasias are congenital abnormalities caused, at least in part, when a group of neurons fail to migrate to the proper area of the brain during development. The cortical tubers observed in ~90% of TSC patients and the pathologic finding for which the disorder is named, are a type of focal cortical dysplasia. Cerebral white matter radial migration lines arise from a similar pathologic process as cortical tubers and other forms of cortical dysplasia and in TSC it is not unusual to find tubers and white matter migrational abnormalities together (Fig 10A). Both types of cortical dysplasia in TSC are commonly associated with intractable epilepsy and learning difficulties in TSC. The pathologic and clinical overlap between “cortical tuber” as a major feature and “cerebral white matter radial migration lines” as a minor feature in the 1998 diagnostic criteria were felt to no longer represent separate processes and are replaced with a single major feature in the new classification “cortical dysplasia.” However, it is appreciated that a single area of focal cortical dysplasia or even two can be observed in an individual who does not have TSC; thus, in the new diagnostic criteria, multiple areas of focal cortical dysplasia count only as one major feature and additional clinical features are necessary to establish a definite diagnosis of TSC.

Subependymal nodules and subependymal giant cell astrocytomas

Subependymal nodules (SEN) and subependymal giant cell astrocytoma (SEGA) will continue to represent two separate major features (Fig 10B). Both of these lesions were also included in the 1998 Consensus Conference Criteria as major features. Histologically, the two lesions are similar and both are relatively specific to TSC although not exclusive to the disorder. Subependymal nodules are benign growths that develop along the wall of the ependymal lining of the lateral and third ventricles. They are observed in 80% of TSC patients and often prenatally detected or at birth. SEGAs
have an incidence of 5-15% in TSC and may also be detected prenatally or at birth, although they are much more likely to arise during childhood or adolescence and it would be unusual for one to occur after the age of 20 years if not already previously present. It is widely accepted that SEGAs typically arise from SEN, especially near the foramen of Monro. Although benign and typically slow-growing, they can cause serious neurologic compromise including obstructive hydrocephalus. Both SENs and SEGAs may progressively calcify over time.

**Cardiovascular features**

The cardiology panel recommended retaining “cardiac rhabdomyoma” as a major feature and determined that there is no need to specify one versus more than one.

**Cardiac rhabdomyoma**

Cardiac rhabdomyomas are benign tumors of the heart that are rarely observed in non-TSC-affected individuals (Fig 11). These lesions usually do not cause serious medical problems, but they are highly specific to TSC and often the first noted manifestation of disease, and therefore remain a major feature. Tumors are most frequently located in the ventricles, where they can compromise ventricular function and on occasion interfere with valve function or result in outflow obstruction. These tumors are frequently observed in TSC-affected individuals during fetal life but after birth, they often regress and in some individuals may no longer be detectable by echocardiographic examination. They are associated with cardiac arrhythmias including atrial and ventricular arrhythmia and the Wolff-Parkinson-White syndrome.

The prenatal presence of a cardiac rhabdomyoma is associated with a 75-80% risk of TSC, with multiple rhabdomyomas conveying an even higher risk. Further, in the era preceding genetic testing, there was a <0.1% occurrence of cardiac rhabdomyoma in individuals not affected with TSC. Because they are frequently observed in fetal life, unlike other findings in TSC, they are important in bringing the patient to medical attention early in life. At that point, new interventions may be more likely to improve prognosis.

**Pulmonary features**

The pulmonology panel recommended retaining the finding of lymphangioleiomyomatosis (LAM) as a major feature of the clinical criteria to diagnose TSC. The other experts agreed with this recommendation.

**Lymphangioleiomyomatosis**

Histologically, LAM is associated with interstitial expansion of the lung with benign-appearing smooth muscle cells that infiltrate all lung structures. Patients typically present with progressive dyspnea on exertion and recurrent pneumothoraces in the third to fourth decade of life. Cystic pulmonary parenchymal changes consistent with LAM are observed in 30-40% of female TSC patients, but recent studies suggest that lung involvement may increase with age such that up to 80% of TSC females are affected by age 40. Cystic changes consistent with LAM are also observed in about 10-12% of males with TSC, but symptomatic LAM in males is very rare. It is important to note that lung is rarely biopsied in TSC patients with pulmonary parenchymal changes, so it is possible that processes other than LAM may result in cystic lung disease in TSC patients. LAM is also diagnosed in individuals who do not have TSC, and is referred to as sporadic LAM (S-LAM). In these patients, LAM is thought to occur through two somatic mutations in the TSC2 gene, rather than through a germline mutation and a “second-hit” somatic mutation that is typical for TSC. That about one third of S-LAM patients have renal angiomyolipomas, another major feature in the diagnostic criteria for TSC, led to the conclusion by the 1998 consensus group that when both angiomyolipoma and LAM were present, other TSC features must be present for the diagnosis of TSC (status per current Consensus Conference discussed in next section).
The precise prevalence of MMPH in patients with TSC is not known, but may be as high as 40-58%. Renal manifestations in TSC are an important source of morbidity and mortality. In the only publication assessing mortality associated with TSC, renal problems in TSC patients were the second leading cause of premature death after severe intellectual disability. With advances in medical care, death in TSC from renal disease is much less likely; however, it continues to represent a significant medical burden to TSC patients.

Angiomyolipomas

Angiomyolipomas are benign tumors composed of vascular, smooth muscle, and adipose tissue (Fig. 13). These benign tumors are observed most commonly in TSC patients in the kidney but can occur in other organs. To be inclusive of angiomyolipomas in other organs, it was decided to delete “renal” and simply use the term “angio-myolipomas (N ≥ 2)” as a major recognized feature. Angiomyolipomas are a feature relatively specific to TSC. Fat-containing angiomyolipomas were observed in 80% of TSC patients, and fat-poor lesions are also common in patients with TSC, but occur in less than 0.1% of the general population. Angiomyolipomas in the kidney can cause serious issues with bleeding because of its vascular nature and can lead to need for dialysis and even renal transplantation.

Multiple renal cysts

Multiple renal cysts are not commonly observed in the general population, but can be seen in TSC patients who...
have a TSC1 or TSC2 mutation or as part of a contiguous gene deletion syndrome involving the TSC2 and PKD1 genes. The TSC2 and PKD1 genes are immediately adjacent and transcribed in opposite directions on chromosome 16p13.3. Deletions involving both genes have been described in a small subset of TSC patients who have the TSC phenotype as well as an aggressive PKD phenotype. Presence of multiple simple renal cysts in older individuals in the general population is well-described, thus the decision was made to specify multiple renal cysts and relegate this feature to the minor status. In cross-sectional studies the number of cysts in healthy people vary with age and standards have been derived to help diagnose specific cystic disease states.

Endocrine features

Limited findings of TSC have been reported in the endocrine system. Various kinds of hamartoma do occur in the endocrine system. According to early reports, adrenal angiomyolipoma can be present in a quarter of TSC patients, but rarely, if ever, causes hemorrhage. Thyroid papillary adenoma have been reported in TSC patients, but did not cause thyroid dysfunction. There are rare case reports of other angiomyolipoma or fibroadenoma in the pituitary gland, pancreas, or gonads. These tumors are considered as representing minor features under the designation “nonrenal hamartomas.” The recommendation was made by the endocrinology panel to retain nonrenal hamartomas as a minor feature to include these findings in the endocrine system of TSC-affected individuals. It was speculated that neuroendocrine tumors might be slightly more prevalent in TSC patients. However, neuroendocrine tumors are not hamartomas and are not considered part of the diagnostic criteria.

Gastrointestinal features

Similarly, gastrointestinal manifestations in TSC patients are fairly rare. Liver angiomyolipomas are reported in 10-25% of TSC patients, and these lesions are included in the major features group under the heading “Angiomyolipomas” (discussed previously). Hamartomatous rectal polyps were included as a minor feature in the 1998 Diagnostic Criteria. It was decided because of the lack of specificity for TSC and because they are another type of “nonrenal hamartoma” that the specific designation of “hamartomatous rectal polyps” would be deleted from the minor criteria.

Acknowledgments

The 2012 International TSC Clinical Consensus Conference was sponsored and organized by the Tuberous Sclerosis Alliance. The conference was supported by generous sponsors who donated funds to the Tuberous Sclerosis Alliance without playing a role in the planning or having a presence at the conference or any influence on the resulting recommendations: the Rothberg Institute for Childhood Diseases, Novartis Pharmaceuticals, Sandra and Brian O’Brien, and Questcor Pharmaceuticals.

References


### Appendix. Members of the 2012 International TSC Consensus Group

**Conference co-chairs:**
- Hope Northrup MD (Houston, Texas)
- Darcy A. Krueger MD, PhD (Cincinnati, Ohio)

**TS Alliance representatives:**
- Steven Roberds PhD (Silver Spring, Maryland)
- Katie Smith (Silver Spring, Maryland)

**Genetics chair:**
- Julian Sampson DM, FRCP, FMedSci (Cardiff, Wales, UK)

**Genetics committee:**
- Bruce Korf MD, PhD (Birmingham, Alabama)
- David J. Kwiatkowski MD PhD (Boston, Massachusetts)
- Mark Nellist PhD (Rotterdam, The Netherlands)

**TS-associated neuropsychiatric disorders chair:**
- Petrus de Vries MBChB, MRCPsych, PhD (Cape Town, South Africa)

**TS-associated neuropsychiatric disorders committee:**
- Anna Byars PhD (Cincinnati, Ohio)
- Kevin Ess MD, PhD (Nashville, Tennessee)
- Dena Hook (Silver Spring, Maryland)
- Anna Jansen MD, PhD (Brussels, Belgium)
- Bryan King MD (Seattle, Washington)
- Mustafa Sahin MD, PhD (Boston, Massachusetts)
- Vicky Whittemore PhD (Bethesda, Maryland)
- Elizabeth Thiele MD, PhD (Boston, Massachusetts)
- E. Martina Bebin MD, MPA (Birmingham, Alabama)

**Epilepsy chair:**
- Elzibeth Thiele MD, PhD (Boston, Massachusetts)

**Epilepsy committee:**
- E. Martina Bebin MD, MPA (Birmingham, Alabama)
- Harry T. Chugani MD (Detroit, Michigan)
- Peter Crino MD, PhD (Philadelphia, Pennsylvania)
- Paolo Curatolo MD (Rome, Italy)
- Greg Holmes MD (Lebanon, New Hampshire)
- Rima Nabbout MD, PhD (Paris, France)
- Finbar O’Callaghan MA, MB, MSc, PhD (Bristol, England, UK)
- James Whelless MD (Memphis, Tennessee)
- Joyce Wu MD (Los Angeles, California)

**Dermatology and dentistry chair:**
- Thomas N. Darling MD, PhD (Bethesda, Maryland)

**Dermatology and dentistry committee:**
- Elizabeth Gosnell DMD (Columbus, Ohio)
- Adelaide Hebert MD (Houston, Texas)
- Greg Mlynarczyk DDS (Santa Rosa, California)
- Keyomaurs Soltani, MD (Chicago, Illinois)
- Joyce Teng MD, PhD (Palo Alto, California)
- Mari Wataya-Kaneda MD, PhD (Osaka, Japan)
- Patricia M. Witman MD (Columbus, Ohio)

**Nephrology co-chair:**
- Chris Kingswood MSc, FRCP (Brighton, England, UK)

**Nephrology co-chair:**
- John Bissler MD (Cincinnati, Ohio)

**Nephrology committee:**
- John Hulbert MD (Edina, Minnesota)
- Lisa Guay-Woodford MD (Washington DC)
- Julian Sampson DM, FRCP, FMedSci (Cardiff, Wales, UK)
- Matthias Sauter MD (Munich, Germany)

**Brain structure, tubers and tumors chair:**
- Sergiusz Jóźwiak MD, PhD (Warsaw, Poland)

**Brain structure, tubers and tumors committee:**
- Ute Bartels MD, MSc (Toronto, Ontario, Canada)
- Moncef Berhouma MD (Lyon, France)
- Mary Kay Koenig MD (Houston, Texas)
- E. Steve Roach MD (Columbus, Ohio)
- Jonathan Roth MD (Tel Aviv, Israel)
- Howard Weiner MD (New York, New York)

**Pulmonology chair:**
- Francis X. McCormack MD (Cincinnati, Ohio)
Pulmonology committee:  
Khalid Almoosa MD (Houston, Texas)  
Alan Brody MD (Cincinnati, Ohio)  
Charles Burger MD (Jacksonville, Florida)  
Vincent Cottin MD (Lyon, France)  
Geraldine Finlay MD (Boston, Massachusetts)  
Jennifer Glass MS (Cincinnati, Ohio)  
Elizabeth Petri Henske MD (Boston, Massachusetts)  
Simon Johnson MD (Nottingham, England, UK)  
Robert Kotloff MD (Philadelphia, Pennsylvania)  
David Lynch MD (Denver, Colorado)  
Joel Moss MD, PhD (Bethesda, Maryland)  
Karen Smith MLS (Bethesda, Maryland)  
Jay Rhu MD (Rochester, Minnesota)  
Angelo Taveira Da Silva MD, PhD (Bethesda, Maryland)  
Lisa R. Young MD (Nashville, Tennessee)  

Cardiology chair:  
Timothy Knilans MD (Cincinnati, Ohio)  

Cardiology committee:  
Robert Hinton MD (Cincinnati, Ohio)  
Ashwin Prakash MD (Boston, Massachusetts)  
Robb Romp MD (Birmingham, Alabama)  

Ophthalmology chair:  
Arun D. Singh MD (Cleveland, Ohio)  

Gastroenterology chair:  
Ashish DebRoy MD (Houston, Texas, USA)  

Endocrinology chair:  
Pei-Lung Chen MD, PhD (Taipei, Taiwan)  

Care Integration chair:  
Steven Sparagana MD (Dallas, Texas)  

Care integration committee:  
Michael D. Frost MD (St. Paul, Minnesota)